C4 therapeutics announces 2023 strategic priorities to advance portfolio of targeted protein degradation medicines

Phase 1/2 trial of cft7455, an ikzf1/3 monodac™ degrader, continues to progress with phase 1 dose escalation data expected in 2h 2023; enrollment open for arm evaluating cft7455 in combination with dexamethasone

CCCC Ratings Summary

CCCC Quant Ranking